J&J's tuberculosis drug gets FDA panel support

11/28/2012 | Reuters

An FDA panel has backed the safety and efficacy of Johnson & Johnson's bedaquiline drug for tuberculosis, but also pointed out possible heart and liver-safety issues. The drug works by targeting the adenosine triphosphate synthase enzyme, which the pathogen requires to generate energy.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA